Extracorporeal photopheresis in BK virus infection after kidney transplantation: current evidence and emerging clinical applications
Clinical Kidney Journal · 02.11.2026 · 19 (11)
DOI: 10.1093/ckj/sfag251 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Kidney Journal, online erschienen am 29.10.2026. Verfasst von Ángela González und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Renal Transplantation, Hospital Clinic, Barcelona, Spain. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BK polyomavirus (BKPyV) infection is a major complication after kidney transplantation, with no approved antiviral therapy and management reliant on immunosuppression reduction, which increases rejection risk. This review outlines the biological rationale for extracorporeal photopheresis (ECP) in infectious settings and critically appraises the current evidence for its use in BKPyV replication and BKPyV-associated nephropathy (BKPyVAN). ECP is an immunomodulatory therapy that induces apoptosis of apheresis-isolated mononuclear cells via ex vivo exposure to a photoactivatable agent and UVA light; reinfusion promotes tolerogenic dendritic cells, regulatory T-cell expansion, and cytokine modulation. Its antiviral potential was first observed in cytomegalovirus, with ECP linked to reduced viral burden in heart, lung, and hematopoietic transplantation. Experience in BKPyV is more limited, restricted to small case series and reports, where ECP combined with immunosuppression reduction was associated with sustained reductions in viremia, reaching >99% in individual series, without increased rejection. These uncontrolled, confounded designs cannot isolate an ECP-specific antiviral effect, and the proposed antiviral mechanism remains hypothetical. ECP may be a promising adjunctive strategy in selected high-risk patients with persistent BKPyV viremia or BKPyVAN, but prospective, controlled studies are needed to confirm efficacy and define optimal use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology and Renal Transplantation, Hospital Clinic, Barcelona, Spain.
- Laboratori Experimental de Nefrologia I Transplantament Renal (LENIT), Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS), Madrid, Spain.
- Department of Medicine, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
- Apheresis Unit, Department of Hemotherapy and Hemostasis, Hospital Clínic Barcelona, Catalonia, Spain.
- Department of Infectious Diseases, Hospital Clínic Barcelona, Catalonia, Spain.
ORCID-Profile: Ángela González, Marc Xipell, Víctor J Escudero-Saiz, Carolt Arana, Jordi Rovira, Miquel Lozano
Zitieren
APA
González, Á., Xipell, M., Escudero-Saiz, V. J., Arana, C., Nicoli, M., Rovira, J., Charry, P., Bodro, M., Ventura-Aguiar, P., Lozano, M., & Diekmann, F. (2026). Extracorporeal photopheresis in BK virus infection after kidney transplantation: current evidence and emerging clinical applications. Clinical Kidney Journal, 19(11). https://doi.org/10.1093/ckj/sfag251
Vancouver
González Á, Xipell M, Escudero-Saiz VJ, Arana C, Nicoli M, Rovira J, et al. Extracorporeal photopheresis in BK virus infection after kidney transplantation: current evidence and emerging clinical applications. Clinical Kidney Journal. 2026;19(11). doi:10.1093/ckj/sfag251
BibTeX
@article{Gonzlez2026,
author = {González, Ángela and Xipell, Marc and Escudero-Saiz, Víctor J and Arana, Carolt and Nicoli, Michael and Rovira, Jordi and Charry, Paola and Bodro, Marta and Ventura-Aguiar, Pedro and Lozano, Miquel and Diekmann, Fritz},
title = {Extracorporeal photopheresis in BK virus infection after kidney transplantation: current evidence and emerging clinical applications},
journal = {Clinical Kidney Journal},
year = {2026},
volume = {19},
number = {11},
doi = {10.1093/ckj/sfag251}
}
EUVIMED